Global Response Aid (GRA), an affiliate of Agility, announced that a Phase 3 US-Canada clinical trial of Avigan®, an anti-viral drug, will continue amid signs the drug could be effective in treatment of patients with mild to moderate cases of COVID-19.
Interim results of the trials indicate that Avigan®, the brand name for generic Favipiravir, could shorten recovery times and prevent progression of COVID-19 in patients in early stages of infection. The US-Canada clinical trial will continue into the summer.
Dubai-based GRA holds joint rights to manufacture, market and distribute Avigan® outside of Japan, China and Russia.

There is no material impact as yet because the drug is not licensed or approved for treatment of COVID-19 in the United States or Canada.


Investor Relations Team

Latest Financial News


June 15, 2022

Confirmation of Corporate Action Dates

Dear Investor, Agility would like to confirm the corporate action dates as per the template. Agility’s General Assembly meeting has …


June 5, 2022

Agility’s New Board Structure

Based on the resolution of Agility’s General Assembly Meeting that was held on May 16, 2022, Agility’s new board structure …


June 1, 2022

Supplement Disclosure: Recommended Cash offer for John Menzies

The board of John Menzies PLC has announced that its shareholders have voted to support a recommended cash offer by …


May 31, 2022

Agility’s Adjourned Extra Ordinary General Assembly Meeting

Dear Investor, Agility Public Warehousing Company KSCP held its Extra Ordinary General Assembly Meeting on Monday May 30th2022 through electronic …